Valuence Merger Corp. I
Key statistics
from XBRL data in SEC filingsAI briefing
from the latest 10-K, 10-Q and 8-K eventsValuence Merger Corp. I is a Cayman Islands blank check company formed in 2021 that raised roughly $220 million in a 2022 IPO and has not yet completed a business combination.
What they do
The company has commenced no operations and generates no operating revenue; all activity since inception relates to formation, its initial public offering, and searching for a target. It intends to concentrate its search on a target based in Asia excluding China, Hong Kong and Macau that is developing breakthrough technology in life sciences and/or advancing a platform for sustainable technology. It is not limited to any particular industry or sector. Until a business combination closes, its only income is non-operating interest income on IPO proceeds.
Revenue drivers
- Interest income on trust account — The company's only income source; proceeds from the IPO and private placement were held in a trust account initially invested in U.S. government securities or money market funds, and since the March 1, 2024 IMTA amendment may be held in an interest-bearing bank deposit account.
- Business combination (future) — No operating revenue will be generated until a business combination is completed, at the earliest; the company has no operating segments today.
- Private placement warrants — 6,666,667 private placement warrants were sold at $1.50 each for $10,000,000, plus 267,995 additional warrants for $401,993 with the over-allotment exercise; these are financing proceeds, not revenue.
Recent performance
The company reported net income of $4.8M in 2023, $2.4M in 2024 and $280,285 in 2025, with operating cash flow negative in every year shown (2023: -$708,533; 2024: -$949,691; 2025: -$396,434). At June 30, 2026 the balance sheet showed total assets of $6.0M, total liabilities of $13.3M and shareholder equity of -$13.2M. Cash and equivalents of $25,017 were reported as of March 31, 2024 in the XBRL data. No operating revenue has been recognized in any period.
Strategy
Management's stated objective is to identify and complete a business combination with one or more businesses, with a focus on targets based in Asia excluding China, Hong Kong and Macau in life sciences breakthrough technology or sustainable technology platforms. The company says it expects to continue to incur significant costs in pursuit of its acquisition plans. Financing came from the March 2022 IPO of 20,000,000 units at $10.00 (plus 2,009,963 over-allotment units) and concurrent private placement warrants. Since March 1, 2024, trust funds may be held in an interest-bearing bank deposit account rather than U.S. government securities or money market funds. The company has not announced a target or signed a definitive business combination agreement in the excerpts provided.
Risks
- No operating history or revenue — The company has no operating results and will not commence operations until a business combination closes, so investors have no basis to evaluate its ability to achieve its objective.
- Failure to complete a combination — If the company fails to complete an initial business combination, it will never generate operating revenues and public shareholders may lose part or all of their investment.
- Shareholders may not get a vote — Under Cayman Islands law certain structures such as asset acquisitions or share purchases would not ordinarily require shareholder approval, so a combination could be completed even if a majority of public shareholders do not support it.
- Negative shareholder equity and liabilities above assets — At June 30, 2026 total liabilities of $13.3M exceeded total assets of $6.0M, leaving shareholder equity of -$13.2M.
Outlook
Management states it expects to continue to incur significant costs in the pursuit of its acquisition plans but cannot assure that its plans to complete a business combination will be successful. The company's only stated use of capital is the search for and consummation of an initial business combination; no target, timeline or combination terms are disclosed in the excerpts provided. Forward-looking statements in the filings flag risks including the ability to select an appropriate target, obtain additional financing and complete a combination.